ArticleACS omega2020
TLC-MS Bioautography-Based Identification of Free-Radical Scavenging, α-Amylase, and α-Glucosidase Inhibitor Compounds of Antidiabetic Tablet BGR-34.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 60 citations in OpenAlex.
- Exploring GC-MS-Based Phytochemistry and Network Pharmacology to Elucidate the Multi-Target Therapeutic Potential of Betel Leaf Oil as an Analgesic and Anti-Inflammatory Agent.Biomedical chromatography : BMC · 2026Article
- A novel Streptomyces zaomyceticus metabolite exhibits antifungal activity against Candida albicans in African catfish.BMC veterinary research · 2026Article
- Article
- Preparation and evaluation of antidiabetic activity of mangiferin-loaded solid lipid nanoparticles.Saudi journal of biological sciences · 2024Article
- System Pharmacological Approach to Investigate and Validate Multitargeted and Therapeutic Effect of Furocoumarins ofAdvances in pharmacological and pharmaceutical sciences · 2024Article
- Utilization of QuinceACS omega · 2023Article
- Evaluation of Antidiabetic Effect of Luteolin in STZ Induced Diabetic Rats: Molecular Docking, Molecular Dynamics, In Vitro and In Vivo Studies.Journal of functional biomaterials · 2023Article
- Multi-Mechanistic and Therapeutic Exploration of Nephroprotective Effect of Traditional Ayurvedic Polyherbal Formulation Using In Silico, In Vitro and In Vivo Approaches.Biomedicines · 2023Article
- Bioactive metabolites ofFrontiers in cellular and infection microbiology · 2023Article
- Article
- Metabolomics and Network Pharmacology in the Exploration of the Multi-Targeted Therapeutic Approach of Traditional Medicinal Plants.Plants (Basel, Switzerland) · 2022Review
- Metabolite Profiling and Nephroprotective Potential of theACS omega · 2022Article
- Metabolomic Profiling and Identification of Antioxidant and Antidiabetic Compounds from Leaves of Different Varieties ofACS omega · 2022Article
- Comparative study of six antidiabetic polyherbal formulation for its multimodal approaches in diabetes management.3 Biotech · 2022Article
- Development of Synergy-Based Combination for Learning and Memory UsingFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BGR-34 is a polyherbal formulation frequently used to combat diabetes around the globe especially in Asian countries. It provides an attractive treatment option to prediabetics, diabetics, and in metabolic disorders by controlling the altered blood glucose level. The lack of phytopharmacological studies on BGR-34 prompted as to reveal the compounds responsible for the antidiabetic and free-radical scavenging activity of BGR-34. An attempt was made to assess
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.